Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation

Initial Closing:
Kurma Partners has secured €140 million in the initial closing of its latest venture capital fund, Biofund IV, with a target of €250 million by 2025.

Investment Strategy:
Biofund IV aims to make 16 to 20 new investments, following a balanced, risk-managed strategy that includes company creation and investments in established venture-stage firms.

Portfolio Companies: The fund has already invested in three promising companies:
SciRhom (autoimmune diseases), Memo Therapeutics (natural immunity), and Avidicure (cancer immunotherapeutics).

Investor Support:
The fund has garnered significant support from both new and returning investors, including Eurazeo, Bpifrance, and pharmaceutical industry investor CSL.

Collaborative Approach:
Kurma Partners employs a collaborative approach, engaging with academic scientists and leveraging its extensive network of industry professionals to foster the success of its portfolio companies.

Proven Track Record:
Kurma Partners has a proven track record of transforming science into marketable products, as evidenced by recent acquisitions from its Biofund III portfolio, including Amolyt Pharma (acquired by AstraZeneca) and Emergence Therapeutics (acquired by Eli Lilly).